ceftizoxime
Sign in to saveCeftizoxime is a third-generation cephalosporin available for parenteral administration. Unlike other third-generation cephalosporins, the whole C-3 side chain in ceftizoxime has been removed to prevent deactivation by hydrolytic enzymes. It rather resembles cefotaxime in its properties, but is not subject to metabolism. It was removed from the US Market in 2007.
Research
1,687 papers- Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.Drugs · 1985
- Ceftizoxime: a beta-lactamase-stable, broad-spectrum cephalosporin. Pharmacokinetics, adverse effects and clinical use.Pharmacotherapy · 1984
- Ceftizoxime and ceftazidime.Lancet (London, England) · 1984
- Ceftizoxime: a third-generation cephalosporin active against anaerobic bacteria. Committee on Antimicrobial Agents, Canadian Infectious Disease Society.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 1990
- [Ceftizoxime: a new aminothiazolyl-syn-methoxy-iminocephalosporin].Medicina · 1990
via PubMed
Article
2 sectionsContents
- Synthesis
- References
{{Drugbox | IUPAC_name = (6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid | image = ceftizoxime.png | image_class = skin-invert-image
| tradename = Cefizox | Drugs.com = | MedlinePlus = a684043 | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =